These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37167277)

  • 21. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study.
    Aypak C; Altunsoy A; Düzgün N
    Ann Clin Microbiol Antimicrob; 2009 Oct; 8():27. PubMed ID: 19852849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial Resistance and Molecular Characterization of Extended-Spectrum β-Lactamases of Escherichia coli and Klebsiella spp. Isolates from Urinary Tract Infections in Southern Brazil.
    Pereira JL; Volcão LM; Klafke GB; Vieira RS; Gonçalves CV; Ramis IB; da Silva PEA; von Groll A
    Microb Drug Resist; 2019 Mar; 25(2):173-181. PubMed ID: 30133334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
    Nicoletti J; Kuster SP; Sulser T; Zbinden R; Ruef C; Ledergerber B; Weber R
    Swiss Med Wkly; 2010; 140():w13059. PubMed ID: 20648400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017.
    Critchley IA; Cotroneo N; Pucci MJ; Mendes R
    PLoS One; 2019; 14(12):e0220265. PubMed ID: 31821338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
    Meier S; Weber R; Zbinden R; Ruef C; Hasse B
    Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study.
    Naber KG; Wagenlehner F; Kresken M; Cheng WY; Catillon M; Duh MS; Yu L; Khanal A; Mulgirigama A; Joshi AV; Ju S; Mitrani-Gold FS
    Sci Rep; 2023 Jul; 13(1):12077. PubMed ID: 37495602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncomplicated urinary tract infections in Swedish primary care; etiology, resistance and treatment.
    Kornfält Isberg H; Melander E; Hedin K; Mölstad S; Beckman A
    BMC Infect Dis; 2019 Feb; 19(1):155. PubMed ID: 30760219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidrug resistance and risk factors associated with community-acquired urinary tract infections caused by Escherichia coli in Venezuela.
    Guzmán M; Salazar E; Cordero V; Castro A; Villanueva A; Rodulfo H; De Donato M
    Biomedica; 2019 May; 39(s1):96-107. PubMed ID: 31529852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoroquinolone-resistant Escherichia coli among the rectal flora is the predominant risk factor for severe infection after transrectal ultrasound-guided prostate biopsy: a prospective observational study.
    Holmbom M; Forsberg J; Fredrikson M; Nilsson M; Nilsson LE; Hanberger H; Hällgren A
    Scand J Urol; 2023 Aug; 58():32-37. PubMed ID: 37553957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1).
    Talan DA; Takhar SS; Krishnadasan A; Abrahamian FM; Mower WR; Moran GJ;
    Emerg Infect Dis; 2016 Sep; 22(9):1594-603. PubMed ID: 27532362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of fluoroquinolone-resistant and broad-spectrum cephalosporin-resistant community-acquired urinary tract infections in Rio de Janeiro: Impact of Escherichia coli genotypes ST69 and ST131.
    de Souza da-Silva AP; de Sousa VS; de Araújo Longo LG; Caldera S; Baltazar ICL; Bonelli RR; Santoro-Lopes G; Riley LW; Moreira BM
    Infect Genet Evol; 2020 Nov; 85():104452. PubMed ID: 32634601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
    Bonkat G; Müller G; Braissant O; Frei R; Tschudin-Suter S; Rieken M; Wyler S; Gasser TC; Bachmann A; Widmer AF
    World J Urol; 2013 Dec; 31(6):1427-32. PubMed ID: 23358791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients.
    Sanchez GV; Baird AM; Karlowsky JA; Master RN; Bordon JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3259-62. PubMed ID: 25063776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Predictive Models to Inform a Novel Risk Categorization Framework for Antibiotic Resistance in Escherichia coli-Caused Uncomplicated Urinary Tract Infection.
    Shields RK; Cheng WY; Kponee-Shovein K; Indacochea D; Gao C; Kuwer F; Joshi AV; Mitrani-Gold FS; Schwab P; Ferrinho D; Mahendran M; Pinheiro L; Royer J; Preib MT; Han J; Colgan R
    Clin Infect Dis; 2024 Aug; 79(2):295-304. PubMed ID: 38573310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact.
    Shin J; Kim J; Wie SH; Cho YK; Lim SK; Shin SY; Yeom JS; Lee JS; Kweon KT; Lee H; Cheong HJ; Park SH; Park DW; Ryu SY; Chung MH; Yoo S; Pai H
    Microb Drug Resist; 2012 Apr; 18(2):169-75. PubMed ID: 22400491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: Prevalence, risk factors, and resistances.
    Pérez Heras I; Sanchez-Gomez JC; Beneyto-Martin P; Ruano-de-Pablo L; Losada-Pinedo B
    Medicine (Baltimore); 2017 Dec; 96(50):e8571. PubMed ID: 29390257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and characteristics of fecal antimicrobial-resistant Escherichia coli in a cohort of Japanese men undergoing prostate biopsy.
    Kamei J; Yagihara Y; Kume H; Horiuchi T; Sato T; Nakagawa T; Fujimura T; Fukuhara H; Moriya K; Homma Y
    Int J Urol; 2017 Apr; 24(4):295-300. PubMed ID: 28222483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal Relatedness, Phylotyping and Antimicrobial Susceptibility of Extended- spectrum-beta-lactamase Producing Uropathogenic Escherichia coli Isolates from Outpatients and Inpatients.
    Azimzadeh N; Derakhshandeh A; Motamedifar M; Naziri Z
    Infect Disord Drug Targets; 2020; 20(5):659-666. PubMed ID: 31322075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.